Pancreatic cancer is one of the most lethal cancers known, with no successful clinical therapy available and a 5-year survival rate of < 5%. Demographic calculations predict that pancreatic cancer will be the second-leading cause of cancer-related deaths by 2030. Hence, the identification of novel drug targets and the subsequent development of novel therapeutic strategies are of utmost importance. The lack of knowledge regarding target antigens that are exclusively expressed or enriched in tumour cells, however, is a major challenge for therapeutic antibody approaches.
展开▼
